Literature DB >> 8384626

Rotavirus-inhibitory activity in serial milk samples from Mexican women and rotavirus infections in their children during their first year of life.

H Brüssow1, O Benitez, F Uribe, J Sidoti, K Rosa, A Cravioto.   

Abstract

A total of 75 children born in rural Mexico were followed for diarrheal diseases and rotavirus (RV) excretion during the first year of life. For 18 children, an average of 14 serial breast milk samples were obtained between days 2 and 360 after delivery and were tested for RV-inhibitory activity. Of these samples, 70, 62, and 85% showed inhibitory activity against serotype (ST) 1 human RV, ST4 human RV, and ST3 simian RV, respectively; the median titers were 10, 10, and 20, respectively. Some 89% of the milk samples showed RV-specific antibodies in an enzyme-linked immunosorbent assay (median titer, 20). Surprisingly, 98% of the milk samples inhibited ST6 bovine RV. ST6, but not ST1, RV-inhibitory activity survived heat treatment (10 min at 80 degrees C). Of the 18 children tested, 13 children experienced 23 episodes of diarrhea (enterotoxigenic [n = 8] and enteropathogenic [n = 3] Escherichia coli, Campylobacter jejuni [n = 4], Shigella flexneri [n = 2], RV [n = 1]) and 5 children experienced 6 RV infections. Only one RV infection was associated with diarrhea. The five RV excretors did not differ from the nonexcretors with respect to the RV-inhibitory activity in the breast milk fed to them. The RV-inhibitory titers were too low in the majority of the studied Mexican milk samples to indicate an important effect of breast-feeding on the take rate of oral human, simian, or reassortant RV vaccines. Breast-feeding might, however, inhibit the take rate of a bovine RV vaccine.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8384626      PMCID: PMC262826          DOI: 10.1128/jcm.31.3.593-597.1993

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  30 in total

1.  Reassortant rotaviruses as potential live rotavirus vaccine candidates.

Authors:  K Midthun; H B Greenberg; Y Hoshino; A Z Kapikian; R G Wyatt; R M Chanock
Journal:  J Virol       Date:  1985-03       Impact factor: 5.103

2.  Dose-response study of RIT 4237 oral rotavirus vaccine in breast-fed and formula-fed infants.

Authors:  T Vesikari; T Ruuska; H Bogaerts; A Delem; F André
Journal:  Pediatr Infect Dis       Date:  1985 Nov-Dec

3.  Secretory antibody directed against rotavirus in human milk--measurement by means of enzyme-linked immunosorbent assay.

Authors:  R H Yolken; R G Wyatt; L Mata; J J Urrutia; B Garciá; R M Chanock; A Z Kapikian
Journal:  J Pediatr       Date:  1978-12       Impact factor: 4.406

4.  Identification of the rotaviral gene that codes for hemagglutination and protease-enhanced plaque formation.

Authors:  A R Kalica; J Flores; H B Greenberg
Journal:  Virology       Date:  1983-02       Impact factor: 3.616

5.  Evaluation of rhesus rotavirus vaccine (MMU 18006) in infants and young children.

Authors:  E L Anderson; R B Belshe; J Bartram; F Crookshanks-Newman; R M Chanock; A Z Kapikian
Journal:  J Infect Dis       Date:  1986-05       Impact factor: 5.226

6.  Clinical efficacy of the RIT 4237 live attenuated bovine rotavirus vaccine in infants vaccinated before a rotavirus epidemic.

Authors:  T Vesikari; E Isolauri; A Delem; E d'Hondt; F E André; G M Beards; T H Flewett
Journal:  J Pediatr       Date:  1985-08       Impact factor: 4.406

7.  Protection of infants against rotavirus diarrhoea by RIT 4237 attenuated bovine rotavirus strain vaccine.

Authors:  T Vesikari; E Isolauri; E D'Hondt; A Delem; F E André; G Zissis
Journal:  Lancet       Date:  1984-05-05       Impact factor: 79.321

8.  Field trial of rhesus rotavirus or human-rhesus rotavirus reassortant vaccine of VP7 serotype 3 or 1 specificity in infants. The Elmwood, Panorama, and Westfall Pediatric Groups.

Authors:  H P Madore; C Christy; M Pichichero; C Long; P Pincus; D Vosefsky; A Z Kapikian; R Dolin
Journal:  J Infect Dis       Date:  1992-08       Impact factor: 5.226

9.  N-acetylneuraminic acid concentrations in human milk oligosaccharides and glycoproteins during lactation.

Authors:  S E Carlson
Journal:  Am J Clin Nutr       Date:  1985-04       Impact factor: 7.045

10.  Effect of fractions of Ethiopian And Norwegian colostrum on rotavirus and Escherichia coli heat-labile enterotoxin.

Authors:  A B Otnaess; I Orstavik
Journal:  Infect Immun       Date:  1981-08       Impact factor: 3.441

View more
  5 in total

1.  Effect of malnutrition on serum and milk antibodies in Zairian women.

Authors:  H Brüssow; D Barclay; J Sidoti; S Rey; A Blondel; H Dirren; A M Verwilghen; C Van Geert
Journal:  Clin Diagn Lab Immunol       Date:  1996-01

2.  Effect of breastfeeding on immunogenicity of oral live-attenuated human rotavirus vaccine: a randomized trial in HIV-uninfected infants in Soweto, South Africa.

Authors:  Michelle J Groome; Sung-Sil Moon; Daniel Velasquez; Stephanie Jones; Anthonet Koen; Nadia van Niekerk; Baoming Jiang; Umesh D Parashar; Shabir A Madhi
Journal:  Bull World Health Organ       Date:  2014-02-04       Impact factor: 9.408

Review 3.  Correlates of protection against human rotavirus disease and the factors influencing protection in low-income settings.

Authors:  E Clarke; U Desselberger
Journal:  Mucosal Immunol       Date:  2014-12-03       Impact factor: 7.313

4.  Evaluating the Impact of Breastfeeding on Rotavirus Antigenemia and Disease Severity in Indian Children.

Authors:  Sushmita Das; Ganesh Chandra Sahoo; Pradeep Das; Utpal Kant Singh; Anil Kumar Jaiswal; Prachi Singh; Ranjeet Kumar; Rishikesh Kumar
Journal:  PLoS One       Date:  2016-02-01       Impact factor: 3.240

5.  Stimulation of rotavirus IgA, IgG and neutralising antibodies in baboon milk by parenteral vaccination.

Authors:  D R Snodgrass; I Campbell; J M Mwenda; G Chege; M A Suleman; B Morein; C A Hart
Journal:  Vaccine       Date:  1995-03       Impact factor: 3.641

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.